LEAP and VentureWell
LEAP and VentureWell Celebrate the Success of the 2023 Ascend MedTech Accelerator Program
August 16, 2023 11:50 ET | Lansing Economic Area Partnership
Lansing, Mich., Aug. 16, 2023 (GLOBE NEWSWIRE) -- The Lansing Economic Area Partnership (LEAP) and VentureWell are thrilled to announce the successful conclusion of the 2023 Ascend MedTech...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs
April 03, 2023 12:45 ET | Medigene AG
Martinsried/Munich, April 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Onconova Logo BLUE.jpg
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
March 23, 2023 08:00 ET | Onconova Therapeutics, Inc.
Collaboration builds off clinical data demonstrating rigosertib’s activity against PLK1 and may inform a precision medicine approach towards rigosertib’s evaluation in new indications Collaboration...
Atyr_Logo.png
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
October 11, 2022 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines...
Logo.png
BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program
March 10, 2022 08:00 ET | BioRestorative Therapies, Inc
MELVILLE, N.Y., March 10, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
cominnex_logo_final_with_tagline.jpg
UPPTHERA and ComInnex sign research collaboration for the development of novel Proteolysis-Targeting Chimera candidates
May 04, 2021 10:00 ET | Custom Chemistry Research
BUDAPEST, Hungary and SEOUL, South Korea, May 04, 2021 (GLOBE NEWSWIRE) -- UPPTHERA, a pharmaceutical venture company aiming for new drugs based on targeted protein degradation (TPD) technology and...
Logo-PharmatherInc.png
PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform
November 18, 2020 07:00 ET | Newscope Capital Corporation
TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the...
provectus_logo.jpg
Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Oral Administration of Rose Bengal Disodium for Cancer Treatment
August 13, 2020 08:00 ET | Provectus Biopharmaceuticals Inc.
University of Calgary researchers have successfully demonstrated initial, in vivo proof-of-concept, oral rose bengal disodium treatment for blood cancerResearchers will now investigate oral treatment...
AskBio-Logo.jpg
CYTOO and AskBio Enter Research Agreement to Screen Gene Therapy Candidates for Rare Muscle Disorder
March 02, 2020 13:21 ET | Asklepios BioPharmaceutical, Inc.
GRENOBLE, France and RESEARCH TRIANGLE PARK, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- CYTOO, a leading drug discovery company on muscle disorders, today announced that it has entered into a research...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
April 01, 2019 16:05 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, April 01, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...